Gefitinib is one of the clinically used TKIs and has been successfully applied to EGFR-driven tumors in the clinic, especially for non-small cell lung cancer (NSCLC) patients with EGFR mutations on exon 18 or exon 21 within the kinase domain 13, 14. This evidence concerns the gene EGFR and non-small cell lung carcinoma.